| 1 |
NCT03272971 |
Recruiting |
Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors |
- Lung Cancer
- Lung Cancer Metastatic
- Lung Cancer, Non-small Cell
|
- Device: Radio-frequency Ablation
|
Interventional |
Not Applicable |
- Broncus Medical Inc
- Uptake Medical Technology, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- RFA relate AEs/SAEs
- Feasibility - Ablated Tissue
- Feasibility - Delivery of Ablation
|
10 |
All |
21 Years to 75 Years (Adult, Senior) |
NCT03272971 |
Protocol 45 |
|
December 5, 2017 |
June 30, 2018 |
July 5, 2018 |
September 6, 2017 |
January 30, 2018 |
|
- The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
|
| 2 |
NCT01694563 |
Completed |
ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal AF |
- Persistent Atrial Fibrillation
- Longstanding Persistent Atrial Fibrillation
|
- Device: Synergy Ablation System
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Primary Efficacy Outcome
- Secondary Efficacy Outcome
- Secondary Safety Outcomes
|
365 |
All |
18 Years and older (Adult, Senior) |
NCT01694563 |
CP2011-1 |
ABLATE-PAS |
September 2012 |
October 23, 2017 |
March 21, 2018 |
September 27, 2012 |
March 22, 2018 |
|
- University of Alabama-Birmingham
Birmingham, Alabama, United States - Scottsdale Healthcare Clinical Research Institute
Scottsdale, Arizona, United States - USC University Hospital
Los Angeles, California, United States - (and 46 more...)
|
| 3 |
NCT01153035 |
Recruiting |
Excision Followed by Radiofrequency Ablation for Breast Cancer |
|
- Device: Radiofrequency Ablation
|
Interventional |
Not Applicable |
- University of Arkansas
- Angiodynamics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Estimate the re-excision rate for close (<3mm) or positive margins
- Decrease local recurrence
|
300 |
Female |
50 Years to 100 Years (Adult, Senior) |
NCT01153035 |
104603 |
ABLATE |
June 2010 |
December 2019 |
June 2020 |
June 29, 2010 |
January 31, 2018 |
|
- University of Arizona
Tucson, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Sharp Oncology (Comprehensive Breast Care of San Diego)
San Diego, California, United States - (and 3 more...)
|
| 4 |
NCT00807924 |
Recruiting |
American Breast Laser Ablation Therapy Evaluation |
- Benign Breast Conditions; Breast Fibroadenomas
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To monitor and measure long term safety and effectiveness Novilase
- To help refine, improve and/or validate breast tumor best practices and standard of care
- To help establish uniform and standardized imaging, pathological assessment and ablation timing protocols
- To support the medical and patient communities through transparency--by contributing and publishing relevant, useful and meaningful data to support the development and design of future research
|
200 |
Female |
18 Years and older (Adult, Senior) |
NCT00807924 |
BR001 |
ABLATE |
December 2008 |
December 2018 |
December 2018 |
December 12, 2008 |
March 31, 2017 |
|
- The Breast Center of Southern Arizona
Tucson, Arizona, United States - Rose Medical Center - Rose Breast Center
Denver, Colorado, United States - Columbia University Medical Center - Department of Surgery
New York City, New York, United States
|
| 5 |
NCT00560885 |
Completed
Has Results |
AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation |
|
- Device: AtriCure Bipolar System
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months.
- Composite Acute Major Adverse Event Rate, Within 30 Days Post-procedure or Hospital Discharge
- Percent of Patients Free From AF, Independent of Antiarrhythmic Drug Status as Determined by Holter Monitoring at 6 Months.
- Composite 6-month Post-procedure Major Adverse Event Rate.
|
55 |
All |
18 Years and older (Adult, Senior) |
NCT00560885 |
CP2007-1 |
ABLATE |
November 2007 |
December 2009 |
December 2012 |
November 20, 2007 |
March 29, 2013 |
March 14, 2013 |
- Mercy Heart Institute
Sacramento, California, United States - Sutter Health
Sacramento, California, United States - Heart Center of Indiana
Indianapolis, Indiana, United States - (and 6 more...)
|
| 6 |
NCT02323854 |
Completed
Has Results |
The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS) |
|
- Device: Ablation
- Procedure: Surgical Resection
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Dose Response
- Ablation Zone Shape
- Number of Participants With Complete or Incomplete Tumor Ablation
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02323854 |
COVEMPR0437 |
EMPRESS |
January 2015 |
March 13, 2017 |
November 2017 |
December 24, 2014 |
April 5, 2018 |
April 5, 2018 |
- Mayo Clinic
Rochester, Minnesota, United States - Weill Cornell Medical College
New York, New York, United States - Rhode Island Hospital
Providence, Rhode Island, United States - University Hospital Frankfurt
Frankfurt, Germany
|
| 7 |
NCT03347227 |
Not yet recruiting |
Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation |
|
- Procedure: Catheter ablation
|
Interventional |
Not Applicable |
- Ottawa Heart Institute Research Corporation
- Heart and Stroke Foundation of Canada
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Freedom from atrial fibrillation (AF)
- Radio frequency ablation delivery time
- Total procedure duration
- (and 4 more...)
|
360 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03347227 |
20170 |
COAST-AF RCT |
June 2018 |
December 2023 |
December 2023 |
November 20, 2017 |
April 11, 2018 |
|
- Libin Cardiovascular Institute
Calgary, Alberta, Canada - Vancouver General Hospital
Vancouver, British Columbia, Canada - London Health Sciences Centre
London, Ontario, Canada - (and 4 more...)
|
| 8 |
NCT02528604 |
Recruiting |
Electrical Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation |
- Persistent Atrial Fibrillation
|
- Procedure: Catheter ablation
- Procedure: Pacemaker and AV node ablation
- Procedure: DC Cardioversion
- Device: Implantable loop recorder
|
Interventional |
Phase 4 |
- Eastbourne General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Quality of life by means of symptom assessment scores.
- AF burden
- Change in peak oxygen consumption (VO2)
- (and 2 more...)
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT02528604 |
CAPAPAF-65 V2.0 |
CAPAPAF-65 |
July 2016 |
October 2017 |
December 2017 |
August 19, 2015 |
February 8, 2017 |
|
- Eastbourne District General Hospital
Eastbourne, East Sussex, United Kingdom - Conquest Hospital
St Leonards-on-Sea, East Sussex, United Kingdom
|
| 9 |
NCT02184013 |
Recruiting |
Correlation of the Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation Study |
- Persistent Atrial Fibrillation
|
- Procedure: Catheter ablation
|
Interventional |
Not Applicable |
- Ottawa Heart Institute Research Corporation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Atrial Fibrillation (AF) Termination
- Radio frequency (RF) ablation time
- Procedure Duration
- Freedom from AF
|
30 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02184013 |
20140623 |
COAST-AF |
August 2015 |
December 2018 |
December 2018 |
July 8, 2014 |
April 24, 2017 |
|
- University of Ottawa Heart Institute
Ottawa, Ontario, Canada
|
| 10 |
NCT01478438 |
Active, not recruiting |
A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers |
|
- Device: Novilase Interstitial Laser Therapy
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Collect information on the proportion of tumors ablated for sample size calculations in the pivotal trial
- To gain experience with the cosmetic outcome and rate of recovery tools
|
60 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT01478438 |
BR-002 |
|
April 2012 |
December 2015 |
December 2020 |
November 23, 2011 |
September 13, 2017 |
|
- The Breast Center of Southern Arizona
Tucson, Arizona, United States - Rose Medical Center - Rose Breast Center
Denver, Colorado, United States - St. Alexius Breast Care of St. Alexius Medical Center
Bartlett, Illinois, United States - (and 9 more...)
|
| 11 |
NCT02307370 |
Completed |
Atherectomy By Laser Ablation With Turbo-Elite |
- Peripheral Arterial Disease
- Peripheral Vascular Disease
|
- Device: Turbo-Elite Laser Catheter
|
Interventional |
Not Applicable |
- Spectranetics Corporation
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary Effectiveness Endpoint (Mean reduction in percent stenosis of greater than 20% by angiographic core lab assessment)
- Primary Safety Endpoint (80% freedom from MAE, all cause death, major amputation in target limb, or TLR)
|
44 |
All |
18 Years and older (Adult, Senior) |
NCT02307370 |
D024204 |
ABLATE |
December 2014 |
November 2015 |
November 2016 |
December 4, 2014 |
April 25, 2017 |
|
|
| 12 |
NCT01877486 |
Withdrawn |
PVI Using Cryoablation Alone in Paroxysmal AF Patients Converted From Persistent AF With Dofetilide |
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation
|
|
Observational |
|
- University of Rochester
- Medtronic
|
Other / Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Freedom from atrial fibrillation/flutter
|
0 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01877486 |
UR Cryo PVI |
ABLATE |
January 2016 |
June 2016 |
December 2016 |
June 13, 2013 |
October 4, 2016 |
|
- Valley Hospital
Ridgewood, New Jersey, United States
|
| 13 |
NCT01464593 |
Terminated |
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC) |
- Colon Cancer Liver Metastasis
|
- Drug: Lyso-Thermosensitive Liposomal Doxorubicin
- Other: 5% Dextrose Solution
- Drug: ThermoDox
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the local tumor control at 1 year post randomization
- Evaluation of Safety
- Time to Local Recurrence
- Overall Survival
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT01464593 |
104-10-201 |
ABLATE |
September 2011 |
May 2013 |
June 2013 |
November 3, 2011 |
March 7, 2016 |
|
- UCLA
Los Angeles, California, United States - Montefiore Medical Center
Bronx, New York, United States - Cleveland Clinic Hospital
Cleveland, Ohio, United States - Rhode Island Hospital
Providence, Rhode Island, United States
|
| 14 |
NCT03035227 |
Enrolling by invitation |
Catheter Ablation of Arrhythmias to Improve CRT Response |
|
- Procedure: Catheter Ablation
- Drug: Anti-Arrhythmics
|
Interventional |
Phase 4 |
- Dhanunjaya Lakkireddy, MD, FACC
- Biosense Webster, Inc.
- University of Kansas Medical Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in Ejection Fraction (EF)
- Bi-ventricular pacing improvement
- Cardiovascular mortality
- (and 6 more...)
|
189 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03035227 |
STUDY00003861 |
ABLATE-CRT |
January 23, 2017 |
December 31, 2018 |
July 31, 2019 |
January 27, 2017 |
April 9, 2018 |
|
- University of Kansas Medical Center
Kansas City, Kansas, United States
|
| 15 |
NCT02009982 |
Completed
Has Results |
Cardioneuroablation for Neurocardiogenic Syncope |
- Neurocardiogenic Syncope
- Vasovagal Syncope
|
- Procedure: Cardioneuroablation
- Device: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
|
Interventional |
Not Applicable |
- David B. De Lurgio
- Biosense Webster, Inc.
- Emory University
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Syncope Recurrence Rate
- Incidence of Serious Adverse Events
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT02009982 |
IRB00062061 |
Ablate-NCS |
December 2013 |
December 2015 |
December 2015 |
December 12, 2013 |
November 4, 2016 |
November 4, 2016 |
- Emory University
Atlanta, Georgia, United States - University of North Carolina
Chapel Hill, North Carolina, United States
|
| 16 |
NCT00925522 |
Completed
Has Results |
Clinical Evaluation of Therapy Cool Path Duo Cardiac Ablation System for the Treatment of Ischemic Ventricular Tachycardia (VT) |
- Ischemic Ventricular Tachycardia
|
- Device: Therapy Cool Path Duo Cardiac Ablation System
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary Safety is Defined as the Incidence of Intra-procedural, Acute or Sub-chronic, Serious Cardiac Adverse Events, up to 7 Days Post-procedure.
- Acute Success is Achieved When All Clinically Relevant VT Substrates (Spontaneous and Induced VT Episodes) Are Terminated and no Longer Inducible Upon Hospital Discharge (i.e., Last Study Ablation Procedure Prior to Hospital Discharge).
- Chronic Success is Defined at 6 Months Following the RF Ablation Procedure as no Recurrence of Clinically Relevant VT(s) That Were Targeted at Ablation.
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT00925522 |
G080076 |
Ablate-VT |
June 2009 |
April 2010 |
July 2011 |
June 22, 2009 |
March 24, 2017 |
May 27, 2016 |
- University Hospital - Univ. of Alabama at Birmingham (UAB)
Birmingham, Alabama, United States - Loyola University Medical Center
Maywood, Illinois, United States - Krannert Institute of Cardiology
Indianapolis, Indiana, United States - (and 2 more...)
|
| 17 |
NCT00115895 |
Active, not recruiting |
The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy |
|
|
Interventional |
Phase 3 |
- Helsinki University
- Helsinki University Central Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cumulative number of radioactive iodine administrations
- Adverse events
- Absorbed radiation dose
- Cancer recurrence
|
160 |
All |
18 Years and older (Adult, Senior) |
NCT00115895 |
SYTJ001T/2000 |
|
January 2000 |
October 2004 |
September 2020 |
June 27, 2005 |
March 2, 2018 |
|
- Helsinki University Central Hospital, Department of Oncology
Helsinki, Finland
|
| 18 |
NCT00094536 |
Completed
Has Results |
Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System |
|
- Device: Extended treatment regimen using Her Option Cryotherapy
|
Interventional |
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Success (Reduction in Menstruation to Normal Levels)
|
82 |
Female |
30 Years to 100 Years (Adult, Senior) |
NCT00094536 |
AMS043 |
|
April 2004 |
October 2007 |
June 2009 |
October 21, 2004 |
March 3, 2017 |
March 3, 2017 |
- Kelly Roy, M.D., P.C.
Phoenix, Arizona, United States - Institute for Women's Health & Body
Wellington, Florida, United States - Lahey Clinic
Burlington, Massachusetts, United States - (and 4 more...)
|
| 19 |
NCT03323905 |
Recruiting |
Single Arm Study Using the Symphony -- MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas |
|
- Device: Symphony MRI guided High Intensity Focused Ultrasound (HIFU)
|
Interventional |
Not Applicable |
- Sunnybrook Health Sciences Centre
- Sunnybrook Research Institute
- Harmonics Medical Inc.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The ability to ablate fibroid tissue
- Treatment effectiveness to reduce fibroid size.
- Incidence of treatment-emerging AEs (safety)
- Confirmation of intended fibroid treatment
|
50 |
Female |
18 Years to 60 Years (Adult) |
NCT03323905 |
HIFUSB |
HIFUSB |
November 16, 2017 |
September 2020 |
September 2022 |
October 27, 2017 |
November 28, 2017 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
| 20 |
NCT01799044 |
Completed |
Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases |
- Colorectal Liver Metastases
- Metastatic Liver Disease
|
- Device: Irreversible electroporation (IRE)
|
Interventional |
Phase 1 |
- Dr. M.R. Meijerink
- VU University Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT01799044 |
NL 41089.029.12 COLDFIRE |
IRE |
November 2012 |
September 2013 |
September 2013 |
February 26, 2013 |
September 4, 2013 |
|
- VU University Medical Center
Amsterdam, Noord-Holland, Netherlands
|
| 21 |
NCT00356057 |
Terminated
Has Results |
Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace |
- Atrial Fibrillation
- Congestive Heart Failure
|
- Device: Protos DR/CLS and Stratos LV CRT pacemakers
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Average Percentage Improvement From Baseline of the 6-minute Walk Test Distance and Minnesota Living With Heart Failure Quality of Life Score at 6-months
- Number of Participants Free of System-related Complications (Related to the Device, Leads, or Implant Procedure) at 6 Months Post-procedure
- Change in Six-minute Walk Test
- (and 9 more...)
|
153 |
All |
18 Years and older (Adult, Senior) |
NCT00356057 |
G040150 |
AVAIL |
December 2004 |
May 2008 |
June 2008 |
July 25, 2006 |
February 27, 2018 |
July 8, 2011 |
- University of Alabama
Birmingham, Alabama, United States - Lake Charles Memorial
Lake Charles, Louisiana, United States - Caritas St. Elizabeth's Medical Center
Boston, Massachusetts, United States - (and 7 more...)
|
| 22 |
NCT00111527 |
Completed |
APAF: Assessment of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation |
- Congestive Heart Failure
- Atrial Fibrillation
|
- Other: Optimized echo-guided CRT pacing
- Other: normal RV pacing
|
Interventional |
Phase 3 |
- Arcispedale Santa Maria Nuova-IRCCS
- Medtronic
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Short-term clinical study (6 months): Quality of life (measured as Minnesota Living with Heart Failure Questionnaire, Specific Symptom Scale and New York Heart Association classification) and exercise capacity at 6 months in the 2 study groups
- Long-term clinical study (24 months): Composite end-point of: death due to cardiovascular cause, hospitalisation for worsening heart failure, worsening heart failure or failure to achieve a persistent subjective symptom improvement (clinical failure)
- The evaluation of the predictive value of echo desynchronisation indexes (inter and intra-LV delays) for identification of clinical failure (see above)
- Cost-benefit comparison of the 2 pacing strategies
|
458 |
All |
18 Years and older (Adult, Senior) |
NCT00111527 |
1893A |
|
May 2005 |
August 2009 |
March 2010 |
May 23, 2005 |
March 23, 2010 |
|
- Michele Brignole
Lavagna, Genova, Italy - Arcispedale S Maria Nuova
Reggio Emilia, Italy
|
| 23 |
NCT03314012 |
Active, not recruiting |
First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension |
|
- Device: Catheter-Based Carotid Body Ablation
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety as assessed by incidence of major adverse events
- Mean reduction in 24-hour ambulatory systolic and diastolic blood pressure
- Composite rate of major adverse events
- (and 3 more...)
|
39 |
All |
18 Years and older (Adult, Senior) |
NCT03314012 |
CL1008 |
|
December 11, 2015 |
August 2018 |
January 2020 |
October 19, 2017 |
April 10, 2018 |
|
- Royal Adelaide Hospital
Adelaide, South Australia, Australia - Fiona Stanley Hospital
Murdoch, Western Australia, Australia - Royal Perth Hospital
Perth, Western Australia, Australia - (and 4 more...)
|
| 24 |
NCT00718991 |
Terminated |
EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study |
- Peripheral Arterial Occlusive Disease
|
- Device: Spectranetics Turbo elite™ excimer laser catheter
|
Interventional |
Phase 2
Phase 3 |
- Flanders Medical Research Program
- Spectranetics Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Angiographic patency for laser + PTA, as defined by < 50% stenosis in the target lesion with straight line flow to the foot
- Absence of Major Adverse Events defined as death, amputation of treated limb and target vessel revascularization
- Immediate angiographic laser recanalization success + PTA, defined as a residual diameter stenosis ≤30% and absence of flow-limiting dissection on visual assessment after combined excimer laser and PTA recanalization treatment
- (and 4 more...)
|
14 |
All |
18 Years and older (Adult, Senior) |
NCT00718991 |
FMRP-005 |
EXCELLENT-BTK |
July 2008 |
July 2009 |
July 2009 |
July 21, 2008 |
March 9, 2015 |
|
- Imelda Hospital
Bonheiden, Belgium - AZ St-Blasius
Dendermonde, Belgium
|
| 25 |
NCT01713244 |
Unknown † |
Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma |
|
- Procedure: RFA assisted Hepatectomy
- Procedure: Hepatectomy
|
Interventional |
Not Applicable |
- Southwest Hospital, China
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence-free Survival
- Overall Survival
|
150 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01713244 |
SKLKF201209 |
|
October 2012 |
October 2016 |
November 2016 |
October 24, 2012 |
November 20, 2015 |
|
- Institute of hepatobiliary surgery,Southwest Hospital
Chongqing, Chongqing, China
|
| 26 |
NCT03381248 |
Recruiting |
Cooled Radiofrequency vs. Hyaluronic Acid to Manage Knee Pain |
- Osteoarthritis of the Knee
|
- Device: Cooled Radiofrequency
- Biological: Hyaluronic Acid
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Numeric Rating Scale (NRS)
- Adverse Events
- Numeric Rating Scale
- Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
|
168 |
All |
21 Years and older (Adult, Senior) |
NCT03381248 |
105-17-0001 |
|
December 7, 2017 |
April 30, 2019 |
October 31, 2019 |
December 21, 2017 |
December 22, 2017 |
|
- Lyman Medical Research
Coeur d'Alene, Idaho, United States - University Orthopedics Center
Altoona, Pennsylvania, United States - University Orthopedics Center
State College, Pennsylvania, United States - (and 2 more...)
|
| 27 |
NCT00196157 |
Unknown † |
Line Versus Spot Ablation in Persistent Atrial Fibrillation |
|
- Procedure: linear anatomically oriented ablations
- Procedure: focal electrophysiological oriented ablations
|
Interventional |
Phase 4 |
- Deutsches Herzzentrum Muenchen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sinus rhythm in follow-up
|
116 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00196157 |
GE IDE No. C00604 |
|
August 2004 |
May 2008 |
November 2008 |
September 20, 2005 |
May 29, 2009 |
|
- Deutsches Herzzentrum Muenchen
Munich, Germany
|
| 28 |
NCT02343003 |
Completed
Has Results |
Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain |
- Osteoarthritis of the Knee
|
- Device: Cooled Radiofrequency
- Drug: Corticosteroid injection
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Numeric Rating Scale (NRS)
- Safety: Number of Subjects Experiencing Adverse Events Through Final Follow up.
- Numeric Rating Scale
- Oxford Knee Score
|
151 |
All |
21 Years and older (Adult, Senior) |
NCT02343003 |
105-14-0001 |
|
January 2015 |
August 2016 |
March 16, 2017 |
January 21, 2015 |
December 26, 2017 |
October 9, 2017 |
- Valley Anesthesiology Consultants - Estrella
Phoenix, Arizona, United States - Valley Anesthesiology Consultants/Valley Pain Consultants
Scottsdale, Arizona, United States - Orthopedic Pain Specialists
Santa Monica, California, United States - (and 8 more...)
|
| 29 |
NCT00523978 |
Completed
Has Results |
A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation |
- Paroxysmal Atrial Fibrillation
|
- Device: Arctic Front® Cryoablation Catheter
- Drug: Flecainide or Sotalol or Propafenone
|
Interventional |
Phase 3 |
- Medtronic Atrial Fibrillation Solutions
- Medtronic
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Acute Procedural Success (APS)
- Freedom From Chronic Treatment Failure (CTF)
- Treatment Success
- (and 2 more...)
|
245 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00523978 |
PS-023 |
Stop-AF |
October 2006 |
August 2010 |
July 2011 |
September 3, 2007 |
August 28, 2012 |
August 28, 2012 |
- University of Alabama
Birmingham, Alabama, United States - Banner Good Samaritan Medical Center
Phoenix, Arizona, United States - Cedar Sinai Medical Center
Los Angeles, California, United States - (and 23 more...)
|
| 30 |
NCT02349971 |
Recruiting |
Safety and Feasibility of MR-Guided High Intensity Focused Ultrasound (MR-HIFU) Ablation of Osteoid Osteoma in Children |
|
|
Interventional |
Not Applicable |
- Children's Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and feasibility measured by the number of patients who are able to be treated with MR HIFU and do not experience significant treatment related adverse events.
- Response
|
14 |
All |
up to 25 Years (Child, Adult) |
NCT02349971 |
HIFU OO |
|
January 2015 |
December 2017 |
December 2018 |
January 29, 2015 |
July 21, 2017 |
|
- Children's National Medical Center
Washington, D.C., District of Columbia, United States
|
| 31 |
NCT01293448 |
Completed |
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium |
- Barrett's Esophagus
- Esophageal Cancer
|
- Device: Cryoballoon Ablation
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment effect
- Post-ablation symptoms
- Post procedure pain
|
21 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01293448 |
CP-0001.A |
|
December 2010 |
January 2012 |
January 2012 |
February 10, 2011 |
January 25, 2018 |
|
- University of Southern California
Los Angeles, California, United States - University of Rochester
Rochester, New York, United States - University of Pittsburgh
Pittsburgh, Pennsylvania, United States - AMC
Amsterdam, AZ, Netherlands
|
| 32 |
NCT00785902 |
Withdrawn |
AtriCure Bipolar Radiofrequency Ablation of Persistent Atrial Fibrillation |
|
- Device: AtriCure Bipolar System
|
Interventional |
Phase 3 |
|
Industry |
|
- The primary efficacy endpoint for this study is the percent of patients free from AF and off Class I and III antiarrhythmic drugs at 9 months.
- The primary safety endpoint is the composite acute major adverse event rate, within 30 days post-procedure or hospital discharge
- The secondary efficacy endpoint for this study is the percent of patients free from AF, independent of antiarrhythmic drug status at 9 months
- The secondary safety endpoint is the composite 9-month post-procedure major adverse event rate.
|
|
All |
18 Years and older (Adult, Senior) |
NCT00785902 |
CP2008-1 |
A |
|
|
|
November 5, 2008 |
February 21, 2011 |
|
|
| 33 |
NCT03181594 |
Active, not recruiting |
Evaluation of the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis |
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in symptom severity
- Frequency of device- and procedure-related serious adverse events
|
100 |
All |
21 Years and older (Adult, Senior) |
NCT03181594 |
CT-0003 |
FROST |
March 2, 2017 |
July 1, 2018 |
April 30, 2019 |
June 9, 2017 |
April 10, 2018 |
|
- California Sleep Institute
East Palo Alto, California, United States - Sacramento Ear, Nose, and Throat
Sacramento, California, United States - San Francisco Otolaryngology Medical Group
San Francisco, California, United States - (and 3 more...)
|
| 34 |
NCT02042859 |
Unknown † |
Radiofrequency Probe for Management of Unresectable Bile Duct and Pancreatic Cancer |
|
- Device: Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in size(patency of bile duct) measured by cholangiography or cholangioscopy, immediately post ablation
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02042859 |
BRFA |
EndoHPB |
February 2013 |
February 2015 |
February 2015 |
January 23, 2014 |
January 23, 2014 |
|
|
| 35 |
NCT01686958 |
Active, not recruiting |
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer |
|
- Device: MR-Guided Transurethral US Ablation of Prostate Tissue
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the frequency and severity of device / treatment related adverse events associated with the use of the investigational system to coagulate prostate tissue.
- Evaluate the effectiveness of the investigation system to thermally coagulate prostate tissue conforming to the target volume with a high degree of accuracy and precision.
|
30 |
Male |
65 Years to 75 Years (Adult, Senior) |
NCT01686958 |
PMI-10246 |
|
March 2013 |
March 2014 |
April 2019 |
September 18, 2012 |
November 30, 2017 |
|
- William Beaumont Hospital
Royal Oak, Michigan, United States - London Health Science Centre
London, Ontario, Canada - German Cancer Research Center (DKFZ)
Heidelberg, Germany
|
| 36 |
NCT00365989 |
Completed |
MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication |
- Uterine Leiomyoma
- Uterine Fibroids
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary end point is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced.
- The secondary end point of the study is to evaluate the ratio of normalized Enhanced Sonication thermal dose volume Vs. that of 'nominal' sonication.
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT00365989 |
UF018 |
|
October 2006 |
August 2008 |
August 2008 |
August 18, 2006 |
March 29, 2018 |
|
- University of California at San Diego
La Jolla, California, United States - Lahey Clinic
Burlington, Massachusetts, United States - KNI
Kalamazoo, Michigan, United States - (and 2 more...)
|
| 37 |
NCT00180739 |
Completed |
Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future |
- Uterine Fibroids
- Pregnancy
|
- Procedure: Magnetic Resonance Guided Focused Ultrasound
|
Interventional |
Phase 4 |
- Imperial College London
- InSightec
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pregnancy outcomes in women who have received treatment with MRgFUS
- Efficacy of MRgFUS as judged by HRQOL questionnaires
|
60 |
Female |
20 Years to 45 Years (Adult) |
NCT00180739 |
UF004 |
|
April 2004 |
|
|
September 16, 2005 |
August 13, 2008 |
|
- St Mary's Hospital
London, United Kingdom
|
| 38 |
NCT03127228 |
Recruiting |
Laser-Assisted Regenerative Surgical Therapy for Peri-implantitis |
|
- Other: Standard mechanical debridement
- Device: Er:YAG laser-assisted debridement
|
Interventional |
Not Applicable |
- University of Michigan
- Morita J USA
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Periodontal Probing Depths (PD)
- Clinical Attachment Level (CAL)
- Gingival Index (GI)
- (and 3 more...)
|
24 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT03127228 |
HUM00124386 |
|
June 26, 2017 |
May 1, 2020 |
May 1, 2020 |
April 25, 2017 |
November 22, 2017 |
|
- University of Michigan School of Dentistry
Ann Arbor, Michigan, United States
|
| 39 |
NCT02828709 |
Recruiting |
Safety and Feasibility of IRE for SRMs |
|
- Device: Irreversible Electroporation
|
Interventional |
Phase 2 |
- Dr. Prof. M.P. Laguna Pes
- Angiodynamics, Inc.
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety IRE ablation procedure (evaluating device and procedural adverse events using CTCAE v4.0)
- Clinical efficacy ((non‐)presence of tumour enhancement on cross‐sectional imaging post IRE)
- Cross sectional imaging post ablation
- (and 4 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02828709 |
NL5693501816 |
|
July 2016 |
July 2018 |
July 2019 |
July 12, 2016 |
September 27, 2016 |
|
- Academic Medical Center (AMC)
Amsterdam, Noord-Holland, Netherlands
|
| 40 |
NCT01596985 |
Unknown † |
Ovarian Endometrioma Ablation Using Plasma Energy Versus Cystectomy |
|
- Procedure: Ablation using the PlasmaJet system
- Procedure: Cystectomy
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Loss of ovarian volume
- Decrease in ovarian antral follicles count (AFC)
- Antimullerian Hormone level (AMH)
|
50 |
Female |
18 Years to 45 Years (Adult) |
NCT01596985 |
P.S.PJ.6.10.GYN |
|
November 2010 |
May 2013 |
May 2013 |
May 11, 2012 |
May 14, 2012 |
|
- University Hospital
Clermont Ferrand, Auvergne, France - University Hospital
Rouen, Seine-Maritime, France
|
| 41 |
NCT02502318 |
Recruiting |
Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer |
|
- Procedure: Video-thoracoscopy
- Procedure: thoracotomy
|
Interventional |
Not Applicable |
- Centre Hospitalier Universitaire Dijon
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The postoperative respiratory complications
- An incremental cost-utility ratio associated with the use of Video-Assisted Thoracic Surgery when compared with thoracotomy evaluated using the quality of life questionnary EQ-5D
|
600 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02502318 |
BERNARD PRME 2014 |
LungSco01 |
July 2015 |
June 2019 |
|
July 20, 2015 |
April 6, 2017 |
|
- CHU Amiens
Amiens, France - Centre Jean Perrin - Clermont-Ferrand
Clermont-Ferrand, France - CHU Dijon
Dijon, France - (and 10 more...)
|
| 42 |
NCT03013257 |
Recruiting |
HIFU vs RAI in the Relapsed Graves' Disease |
|
|
Interventional |
Not Applicable |
- The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of remission
- Incidence of treatment-related morbidities from day-0 to post 2-week
- Change in auto-antibodies
- (and 7 more...)
|
266 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03013257 |
UW 16-565 |
|
April 25, 2017 |
December 2018 |
June 2019 |
January 6, 2017 |
July 17, 2017 |
|
- Queen Mary Hospital
Hong Kong, Hong Kong
|
| 43 |
NCT00265629 |
Completed |
RF Ablation of Atrial Fibrillation |
|
- Device: RF catheter ablation
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the safety of the HDMA when used to map & ablate patients with AF, by assessing MCs at 7-days & 30 days post-procedure & assessing the occurrence of pulmonary vein stenosis at 3 & 12 months post-procedure.
- Evaluate the preliminary effectiveness of the HDMA when used to map and ablate patients with paroxysmal AF, by assessing APS & the freedom from recurrence of symptomatic AF at 3, 6 & 12 months post- procedure.
|
20 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT00265629 |
BEP-4405 |
|
August 2005 |
September 2009 |
October 2009 |
December 15, 2005 |
June 19, 2013 |
|
- David Haines, MD
Royal Oak, Michigan, United States
|
| 44 |
NCT00650988 |
Completed |
Cryotherapy for Barrett's Esophagus and Early Esophageal Cancers |
- Barretts Esophagus
- Esophageal Cancer
|
- Procedure: Cryospray Ablation
|
Interventional |
Early Phase 1 |
- Case Comprehensive Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients that achieved successful ablation of dysplasia and neoplasia Barrett's Esophagus.
- Number of patients that experience toxicity with cryotherapy
- Assess the degree of tumor ablation of inoperable early esophageal cancer
|
37 |
All |
18 Years and older (Adult, Senior) |
NCT00650988 |
CASE5205
Cleveland Clinic IRB 8270 |
|
September 2005 |
May 2008 |
December 2008 |
April 2, 2008 |
December 24, 2012 |
|
- The Cleveland Clinic
Cleveland, Ohio, United States
|
| 45 |
NCT02010801 |
Completed |
Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors |
|
- Procedure: irreversible electroporation
- Device: nanoknife AngioDynamics US Ltd
|
Interventional |
Not Applicable |
- National Taiwan University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete treatment
- adverse effect
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02010801 |
201010036D |
|
April 2012 |
December 2013 |
December 2013 |
December 13, 2013 |
December 13, 2013 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 46 |
NCT01972867 |
Withdrawn |
Pilot Study of NanoKnife for Ablation of Prostate Cancer in Low Risk Patients |
|
- Device: NanoKnife Procedure
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
0 |
Male |
50 Years to 70 Years (Adult, Senior) |
NCT01972867 |
ON-NK310 |
|
November 2013 |
August 2016 |
August 2016 |
October 31, 2013 |
February 11, 2016 |
|
- Duke University
Durham, North Carolina, United States
|
| 47 |
NCT01446419 |
Completed
Has Results |
SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain |
|
- Device: Intracept Treatment
- Device: Sham Treatment
|
Interventional |
Not Applicable |
- Relievant Medsystems, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in ODI From Baseline to 3 Months Post-treatment
- Patient Success at 3 Months
- Change in ODI From Baseline to 6 Months Post-treatment
|
225 |
All |
25 Years to 70 Years (Adult, Senior) |
NCT01446419 |
CIP 0003 |
SMART |
October 2011 |
March 2015 |
March 2016 |
October 5, 2011 |
October 31, 2016 |
October 31, 2016 |
- Desert Institute for Spine Care
Phoenix, Arizona, United States - SpineCare Medical Group
Daly City, California, United States - Memorial Orthopedic Surgical Group
Long Beach, California, United States - (and 10 more...)
|
| 48 |
NCT03094221 |
Completed |
Clinical Utility and Validation of the Rhythmia Mapping System for the Treatment of Cardiac Arrhythmias |
- Cardiac Arrhythmias
- Electroanatomic Mapping
- Cardiac Ablation
|
- Device: Rhythmia Mapping System
|
Observational |
|
- Beth Israel Deaconess Medical Center
- Boston Scientific Corporation
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Arrhythmia Mapping (Yes/No)
- Ablation Success - Elimination of Clinical Arrhythmia (Yes/No)
- Mapping Time (minutes)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03094221 |
2014P000240 |
|
January 13, 2015 |
December 1, 2015 |
December 1, 2015 |
March 29, 2017 |
March 29, 2017 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
| 49 |
NCT02766543 |
Active, not recruiting |
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer |
|
- Device: MRI-guided Transurethral Ultrasound Ablation
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety Endpoint - Incidence of treatment-emergent adverse events
- Efficacy Endpoint - Proportion of patients achieving a PSA nadir ≤ 25% of the pre-treatment baseline value.
- Erectile Dysfunction Endpoint
- (and 12 more...)
|
115 |
Male |
45 Years to 80 Years (Adult, Senior) |
NCT02766543 |
GCP-10100 |
|
September 21, 2016 |
December 2018 |
December 2022 |
May 9, 2016 |
February 12, 2018 |
|
- University of California Los Angeles
Los Angeles, California, United States - University of Chicago
Chicago, Illinois, United States - Indiana University
Indianapolis, Indiana, United States - (and 10 more...)
|
| 50 |
NCT01716598 |
Completed |
Evaluation of the IPS System for TLD Therapy in Patients With COPD |
- Chronic Obstructive Pulmonary Disease (COPD)
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary Safety Endpoint
- Performance
|
15 |
All |
40 Years and older (Adult, Senior) |
NCT01716598 |
CLP-002
CVI-12-03-005102 |
IPS-II |
October 2012 |
May 2014 |
April 2016 |
October 30, 2012 |
September 23, 2016 |
|
- Otto-Wagner Hospital and Medical Center
Sanatoriumstrasse 2, Vienna, Austria - Centre Hospitalier et Universitaire de Grenoble
Grenoble, France - Centre Hospitalier University de Reims
Reims, France - Nouvel Hopital Civil
Strasbourg, France
|
Create an RSS feed from your search for:
Download the search results for: